Global Regulation of Nucleotide Biosynthetic Genes by c-Myc by Liu, Yen-Chun et al.
Global Regulation of Nucleotide Biosynthetic Genes by c-
Myc
Yen-Chun Liu
1, Feng Li
2, Jesse Handler
2, Cheng Ran Lisa Huang
3, Yan Xiang
2, Nicola Neretti
5,6, John M.
Sedivy
5, Karen I. Zeller
2*, Chi V. Dang
1,2,3,4*
1Program in Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2Division of Hematology, Department of
Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 3Program in Human Genetics and Molecular Biology, Johns
Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 4The Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University
School of Medicine, Baltimore, Maryland, United States of America, 5Department of Molecular Biology, Cell Biology and Biochemistry, and Center for Genomics and
Proteomics, Brown University, Providence, Rhode Island, United States of America, 6Institute for Brain and Neural Systems, Brown University, Providence, Rhode Island,
United States of America
Abstract
Background: The c-Myc transcription factor is a master regulator and integrates cell proliferation, cell growth and
metabolism through activating thousands of target genes. Our identification of direct c-Myc target genes by chromatin
immunoprecipitation (ChIP) coupled with pair-end ditag sequencing analysis (ChIP-PET) revealed that nucleotide metabolic
genes are enriched among c-Myc targets, but the role of Myc in regulating nucleotide metabolic genes has not been
comprehensively delineated.
Methodology/Principal Findings: Here, we report that the majority of genes in human purine and pyrimidine biosynthesis
pathway were induced and directly bound by c-Myc in the P493-6 human Burkitt’s lymphoma model cell line. The majority of
these genes were also responsive to the ligand-activated Myc-estrogen receptor fusion protein, Myc-ER, in a Myc null rat
fibroblast cell line, HO.15 MYC-ER. Furthermore, these targets are also responsive to Myc activation in transgenic mouse livers
in vivo. To determine the functional significance of c-Myc regulation of nucleotide metabolism, we sought to determine the
effect of loss of function of direct Myc targets inosine monophosphate dehydrogenases (IMPDH1 and IMPDH2) on c-Myc-
induced cell growth and proliferation. In this regard, we used a specific IMPDH inhibitor mycophenolic acid (MPA) and found
that MPA dramatically inhibits c-Myc-induced P493-6 cell proliferation through S-phase arrest and apoptosis.
Conclusions/Significance: Taken together, these results demonstrate the direct induction of nucleotide metabolic genes by
c-Myc in multiple systems. Our finding of an S-phase arrest in cells with diminished IMPDH activity suggests that nucleotide
pool balance is essential for c-Myc’s orchestration of DNA replication, such that uncoupling of these two processes create
DNA replication stress and apoptosis.
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Introduction
MYC, which encodes the c-Myc (herein termed Myc)
transcription factor, is frequently altered in human cancers [1–
3]. A compilation of Myc regulated genes and studies on
alterations of MYC in human cancers are available on-line at
www.myccancergene.org [4]. This compilation highlights the
critical role of MYC in human cancers and the importance of
Myc target genes in mediating its oncogenic activity. The causal
role of MYC in tumorigenesis is underscored by the tumors arising
from its ectopic expression in various tissues of transgenic mice [5–
9]. Subsequent to initial studies demonstrating that forced
expression of MYC in lymphoid tissues resulted in lymphoid
hyperplasia and lymphomas, virtually all other studies of
constitutive or inducible MYC in tissues from skin to liver resulted
in neoplastic transformation of the targeted tissue. Studies with
these models have also revealed that MYC mediated tumorigen-
esis includes the concurrent activation of cell growth and
proliferation along with inactivation of apoptotic pathways in a
tissue specific fashion [8,9].
The Myc protein heterodimerizes with Max to bind DNA,
stimulate and repress transcription[10–12]. The Myc-Max
network is quite complex, particularly since Max also interacts
with six other proteins including Mxd1, Mxd2, Mxd3, Mxd4,
Mnt, and Mga[13–15]. Many of these non-Myc heterodimers
could counter the function of Myc. These findings paint an
emerging picture of Myc as an oncogenic transcription factor that
is involved in a complicated Max-associated network of proteins to
regulate gene expression. Recent findings, however, indicate that
Myc also has non-transcriptional functions as well as a role in
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stimulates mRNA cap methylation in the absence of the Myc
DNA binding domain[17,18].
The biological properties of MYC in cell culture and in vivo
models suggest that Myc plays a pleiotropic role through its target
genes in the regulation of cell size and proliferation as well as
cellular metabolism and adhesion. In fact, MYC has emerged as a
master regulator that couples cell proliferation to metabolism. To
date direct and indirect Myc target genes have been implicated in
a variety of cellular processes[19–21]. Since MYC induces cell
proliferation under specific circumstances, a group of Myc target
genes-as expected-involves cell cycle regulation[22,23]. Activation
of positive cell cycle regulators, such as CDK4, and suppression of
negative cell cycle effectors, such as p21, have been reported[24–
27]. In particular, CDK4 has been directly implicated downstream
of MYC in the skin tumorigenesis through the use of CDK4 gene
deletion in mice [28].
MYC has been connected to different metabolic pathways
through its regulation of target genes such as CAD (nucleotide
metabolism) [29], ODC (ornithine/spermine metabolism) [30],
LDHA (glucose metabolism) [31] and SHMT2 (single carbon
metabolism) [32]. Global gene expression analysis now connects
MYC with diverse metabolic pathways with an overrepresentation
of Myc responsive genes involved in glucose and nucleotide
metabolism. Although Myc’s regulation of glucose metabolism has
been well delineated, the connection between Myc and purine or
pyrimidine metabolism is not well understood. It stands to reason,
however, that a master regulator such as Myc must somehow
couple cell cycle traversal through S-phase with regulation of
nucleotide metabolism and energy generation.
Our global mapping of MYC binding sites in a human B cell
lymphoma model identified over 2000 binding sites with 668 direct
Myc target genes gleaned from accompanying microarray gene
expression analysis [33]. Among the direct Myc target genes is a
statistically over-represented small set involved in nucleotide
metabolism. This observation led us to determine comprehensively
whether genes involved in both purine and pyrimidine synthesis
pathways are directly regulated by Myc. We observed that virtually
all genes involved in nucleotide de novo synthesis are up-regulated and
bound by Myc. Although many nucleotide metabolic genes are up-
regulatedbyMyc-ERinMycnullratfibroblasts,onlyphosphoribosyl
pyrophosphate amidotransferase (PPAT) and dihydroorotate dehy-
drogenase (DHODH) survived the criterion of cycloheximide
treatment, which would prevent indirect activation of targets.
Cycloheximide, however, was found to be very problematic due to
the noise induced by cycloheximide treatment alone.
To determine the effect of loss of function of target genes
involved in nucleotide biosynthesis on MYC-responsive B cell
proliferation, we used a specific pharmacological inhibitor of
inosine monophosphate dehydrogenase (IMPDH), mycophenolic
acid (MPA), and found that inhibition of IMPDH caused DNA
replication stress, apoptosis and DNA replication arrest in B cells
with high ectopic MYC expression. This arrest was rescued by a
downstream metabolite precursor, guanosine, suggesting that
maintenance of a balanced nucleotide pool is essential for proper
DNA synthesis and cell proliferation. Our studies demonstrate a
link between MYC, a master regulator of cell growth and
proliferation, and the regulation of nucleotide biosynthesis genes.
Materials and Methods
Cell culture
Human Burkitt’s lymphoma cell line P493-6, carrying an
inducible MYC repression system, was a generous gift of D. Eick
(InstituteforClinicalMolecularBiology and Tumor Genetics,GSF-
Research Centre, Munich, Germany). Cells were cultured in RPMI
1640, 10% fetal bovine serum, and 1% penicillin/streptomycin.
Tetracycline (Sigma) treatment at 0.1 mg/ml for 48 hrs was used to
repress the ectopic c-MYC expression. Ramos cells were obtained
from ATCC and cultured in RPMI 1640, 10% fetal bovine serum,
and 1% penicillin/streptomycin. For mycophenolic acid (Sigma,
dissolved in methanol) and guanosine (sigma, dissolved in 1M acetic
acid) treatment, cells were placed in RPMI medium containing the
indicated reagents. For growth rate experiments, colorimetric
microplate assay Cell Counting Kit-8 (Dojindo) was used according
to the manufacturer’s instructions. In every 96 well, 15000 Ramos
cells or 25000 P493 cells were plated. At 48hr time point, another
100 ml of fresh medium with designated treatment was added.
Tetrazolium salt was added to achieve a final concentration of 10%
at different time points. Absorbance was measured at 450 nm after
3.3 hour incubation. All experiments were performed in triplicates.
HO.15MYC-ER,aMYC-/-ratfibroblastcelllineoverexpressing
the MYC-ER construct was maintained in DMEM and 10% fetal
bovine serum. These cells were previously described [34,35]. In the
MYC-ER induction experiment, HO.15 MYC-ER cells are cultured
in either regular medium (DMEM+10%FBS) or serum starvation
(DMEM+0.25% FBS) for 48 hrs before the 4-hydroxytamoxifen
stimuli. Cells are treated with cycloheximide (10 mM) or DMSO
vehicle ctrl for 30 minutes before the 4-hydroxytamoxifen (250nM)
or ETOH vehicle ctrl was added to the tissue culture medium. Cells
were collected for RNA extraction at time points: 0 hr, 2 hr, 4 hr and
10 hr after the addition of 4-hydroxytamoxifen. [36]
Western blot analysis
For immunoblot analysis, cells were lysed in incomplete Laemmli
buffer (lacking b-mercaptoethanol and dye) and subsequently boiled
at 95uC for 5 minutes before quantification. Protein concentration
was measured by using a bicinchoninic acid kit (Pierce). Samples of
15 to 20 micrograms of protein with b-mercaptoethanol and dye
were loaded on the Nupage H Bis-Tris 4-12% gradient gel
(Invitrogen) and transferred to a nitrocellulose membrane. The
protein expression of c-Myc was detected by 9E10 antibody
produced from ascites with the original hybridoma clone.
In vivo analysis of nucleotide de novo synthesis in murine
neonatal hepatocarcinoma
The conditional c-MYC-transgenic neonatal hepatocellular
carcinoma model was previously described[37]. The animals were
maintained on regular drinking water or water supplemented with
0.01% doxycycline when the female LAP-tTA and the male TRE-
Myc transgenic mice were crossed and maintained as it was after
the babies were born till 11 days to collect the liver tissue.
Chromatin immunoprecipitation
Untreated P493-6 cells, cells subjected to Tetracycline treat-
ment for 48 hours, and cells withdrawn from Tetracycline
treatment at different time points (6 hr, 10 hr, and 26 hrs) were
used for chromatin immunoprecipitation (ChIP) assays. Chroma-
tin was immunoprecipitated with the rabbit polyclonal c-MYC (sc-
764; Santa Cruz Biotechnology) and human hepatocyte growth
factor (sc-7949; Santa Cruz) antibodies as previously de-
scribed[4,33,38]. Total input controls were collected from the
supernatant of the ‘‘no antibody’’ control.
Double thymidine block
Synchronization of P493-6 cells was achieved by incubating
cells with 2mM thymidine for 12 hours, washing and incubating
Myc and Nucleotide Metabolism
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treating cells with a second time thymidine for 12 hours[39–42].
After washing, cells were subsequently treated with either vehicle
or the MPA and guanosine combination as indicated. Cells were
collected for cell cycle profiles at different time points (4 h, 8 h,
and 12 h) after the double thymidine block. Cell cycle profiles
were analyzed by using propidium iodide (PI) staining[43].
Flow cytometry
For PI staining, 1610
6cells were re-suspended and fixed with
70% ethanol at 220uC for at least an hour. Before analysis, cells
were re-suspended in PBS containing 100 mg/ml RNaseA (Roche)
and 50 mg/ml PI (Sigma) for at least an hour.
For BrdU uptake assay, FITC BrdU Flow Kit (BD Pharmingen)
was used. Approximately 1610
6cells were pulsed with 10 mM
BrdU in the regular medium (RPMI1640+10%FBS+1%Pen/
strep) for 30minutes before subsequent fixation and staining
according to manufacturer’s instructions.
For apoptosis detection, Annexin V-PE Apoptosis Detection kit
I (BD Pharmingen) was used according to the manufacturer’s
instructions. Cells were filtered and then analyzed using a Becton
Dickinson FACScan or FACSCalibur flow cytometer.
Real-time PCR
Quantitation of ChIP fragments was performed as described
[33] using the Power SYBR Green PCR Master Mix (ABI)
according to the manufacturer’s instructions with the ABI 7700
sequence detection system or ABI 7500 Realtime PCR system.
Specific primers were designed using the Primer Express software
(supplemental Table S3). Known quantities of 10-fold dilutions
of total input DNA were used to generate standard curves for each
primer pair. Relative amounts of each ChIP sample (expressed as
the percentage of total input) were determined in the linear range
according to their CT value. Dissociation curves were used to verify
the correct PCR product for each primer pairs.
Total RNA was extracted from P493-6 cells with RNeasy kit
(QIAGEN) or extracted from mouse liver tissue with Trizol
(Invitrogen). cDNA was obtained by using Taqman reverse
transcription reagents. To examine the expression level of the
nucleotide de novo synthesis, primers were designed to cross exon-
exon junctions (supplemental Table S2) and the Power SYBR
Green PCR Master Mix (ABI) was used. Human c-MYC was
detected with primers (Forward: TCAAGAGGTGCCACG-
TCTCC, Reverse: TCTTGGCAGCAGGATAGTCCTT) and
probe (CAGCACAACTACGCAGCGCCT) with the TaqMan
Universal PCR Master Mix(ABI). A predeveloped probe and
primers specific to 18S rRNA levels were used for normalization.
All PCRs were performed in triplicates.
HO.15 MYC-ER microarray
Cell culture for array analysis and expression
profiling. The cell line HOMycER12 was used [34,35]. This
cell line was derived from the c-myc-/- cell line HO15.19, and
expresses a cDNA encoding a c-Myc -estrogen receptor (ER)
fusion protein. MYC-ER cells were kept in a constant state of
proliferation and the MYC-ER protein was activated by addition
of 4-hydroxytamoxifen (OHT) to the medium, as described [35].
Cells were collected at the following time (t) points after addition of
OHT: 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours. A sample was
also collected at the time of OHT addition (t=0 h). Negative
controls were collected at 8 h, 16 h and 24 h following mock
addition of OHT (ethanol vehicle). Total RNA was harvested from
each sample, and was hybridized to GeneChip (r) Rat Exon 1.0
ST Arrays (Affymetrix). The entire process was repeated to
generate three independent biological replicates.
Probeset filtering and normalization. The PLIER
algorithm from the Affymetrix Power Tools (APT) software
package was used to generate gene and exon expression scores.
Probes were filtered and remapped according to the ENTREZG
tables provided by the Microarray Lab of the Molecular and
Behavioral Neurosience Institute, University of Michigan[44].
Probes were remapped by blasting their sequences onto the rn4
genome and removing probes mapping to multiple locations in the
genome. Genes were redefined as sets of at least three probes
mapping to the same Entrez gene designation. These data will be
deposited in the National Center for Biotechnology Information
Gene expression Omnibus (GEO).
Statistical Analysis of microarray data. We first excluded
from the analysis genes whose PLIER scores, averaged over the
three biological replicates, did not exceed a value of 48 for all time
points, (the 1st quartile of all the average scores over all replicates,
which we considered below the noise threshold). We then applied
a 3-way ANOVA with the following factors: time, treatment, and
experiment (each biological replicate and its associated controls
were considered as one independent experiment). The experiment
factor was included since we have evidence that scores from the
same experiment are correlated. For each gene, the time factor p
value was calculated based on differential expression between any
time point (t ‘‘greater or equal to’’ 1 h) and the t=0 time point;
the treatment factor p value was calculated based on differential
expression between treated and control samples. The p-value
threshold was set using a Bonferroni correction, in which the p-
value cutoff (0.05) is divided by the number of genes (21,334). After
this analysis, 1,612 genes were deemed significantly differentially
expressed following c-MYC induction.
Results
Myc upregulates the expression of nucleotide de novo
genes in vitro
From our previous genome-wide mapping of Myc binding sites
via coupling chromatin immunoprecipitation with pair-end ditag
sequencing analysis (ChIP-PET) in P493-6 cells [33], we found that
among sets of genes bound by Myc, nucleic acid metabolism is one
of the most significantly enriched functional class based on Gene
Ontology categorization through the PANTHER database
(panther.appliedbiosystems.com). The P493-6 cell line, an EBV
immortalized B lymphocyte engineered with a tetracycline (Tet)-
repressible c-MYC expression vector, is considered as an in vitro
Burkitt’s lymphoma model [45]. P493-6 cells express high levels of
Myc in the absence of tetracycline with a Burkitt’s lymphoma-like
cytologic morphology. Within the purine and pyrimidine de novo
synthesis pathway, 11 genes were bound directly by Myc in the
ChIP-PET study (Figure 1). Genes encoding almost every step
involved in the purine and pyrimidine de novo synthesis pathway
are up-regulated after MYC induction in the P493-6 system as
determined by 5 microarray experiments on biological duplicates or
triplicates. The majority of the nucleotide biosynthesis genes were
also found to have canonical E boxes within either their promoters
or first introns (supplemental Table S1). Altogether, these
findings strongly indicate that MYC could bind and presumably
directly activate both purine and pyrimidine synthesis genes.
To delineate if Myc directly regulates the nucleotide de novo
biosynthetic genes, the expression levels of these genes in response
to Myc were examined and ChIP assays were performed. We used
quantitative real-time PCR (qPCR) to assay mRNA levels and
ChIP products in P493-6 cells.
Myc and Nucleotide Metabolism
PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2722Figure 1. Purine and pyrimidine biosynthesis pathways. The inset provides a legend of nucleotide metabolism genes with direct MYC binding
found by ChIP-PET in P493-6 model [33].
doi:10.1371/journal.pone.0002722.g001
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separately at different time points after tetracycline withdrawal to
elucidate the kinetics of nucleotide biosynthetic gene induction by
MYC. While Myc protein level increases by 4 hours (Figure 2,
inset), qPCR assays showed significant induction of all 11 genes
examined between 6 to 12 hours after removal of tetracycline
(Figure 2). The observations of the temporal response of
nucleotide biosynthesis genes to Myc support a role for Myc in
regulating nucleotide metabolism in the B cell model.
c-MYC upregulates the expression of nucleotide
biosynthetic genes in vivo
Since most of the nucleotide biosynthetic gene expression level
is tightly coupled to Myc expression in vitro in the human B
lymphocyte model, we sought to characterize whether selected
nucleotide metabolic genes are also induced by Myc in vivo.W e
used a murine inducible MYC transgenic hepatocarcinoma model
that provides ample tissue for gene expression analysis. The TRE-
LAP MYC transgenic mice over-express human MYC in liver cells
upon removal of doxycycline from the drinking water resulting in
hepatocellular carcinoma (HCC) in neonates from pregnant
females [37]. While neonates up to 3 days do not develop HCC
even with high MYC expression, neonates at 6 days of age or older
demonstrated liver cancer cells that effaced the entire liver. By
neonatal day 11, all animals have HCC. In this model, ectopic
MYC expression is induced nearly 10-fold in non-tumorous livers
above doxycycline-treated controls. The expression of MYC is
further increased in tumor cells by an additional 10-fold through
an unknown mechanism [37]. We sought to study the expression
of PPAT, PAICS, IMPDH1, IMPDH2 and DHODH in these
livers. We were interested in PPAT and PAICS because they share
a bi-directional promoter and are both key enzymes in purine
synthesis (Figure 1). For IMPDH and DHODH, there are
clinically available small molecules that could specifically inhibit
their function separately. We compared the expression of these
selected nucleotide biosynthesis genes by qPCR at neonatal day 3,
6 and 11 in livers from 3 animals in each group treated (-MYC) or
untreated (+MYC) with doxycycline (Figure 3). Note that in the
absence of tumor formation at day 3, the expression of PPAT,
IMPDH1, IMPDH2, DHODH but not PAICS are all statistically
significantly elevated with MYC induction. The expression levels
were further increased in the tumors at neonatal day 11. These
observations indicate that, all the genes examined except PAICS
are all responsive to MYC in vivo.
Myc directly binds to the regulatory regions of
nucleotide biosynthetic genes in the human P493 B cells
We determined the binding of Myc to the promoters or intronic
sequences of specific nucleotide metabolic genes to provide
additional evidence for their direct regulation by Myc. As shown
in Figure 4, Myc bound most of these genes except GMPS. The
binding was dependent on the induction of Myc protein. The
primers used in the ChIP experiment amplified regions that are
proximal to canonical E boxes or PET-clusters identified by ChIP-
PET study. For genes without canonical E box or PET-cluster,
primers were designed to cover the promoter region. The binding
of Myc to most nucleotide metabolic genes strongly supports the
hypothesis that Myc directly activates nucleotide biosynthesis.
The MYC-ER system validates PPAT and DHODH as direct
c-MYC target genes in rat fibroblasts
The Myc-estrogen receptor hormone binding domain (Myc-ER)
fusion protein system is another important model for the
Figure 2. Nucleotide biosynthetic genes are responsive to MYC induction in human B cells in vitro. The expression of the nucleotide
synthetic genes is temporally responsive to Myc induction. The inset shows an immunoblot of Myc expression in P493-6 cells withdrawn from
tetracycline. Bar graphs represent mRNA expression of each indicated nucleotide synthetic gene relative to 18S rRNA control as determined by
triplicate real-time PCR reactions (with less than 5% error from the mean) in P493-6 cells with a time course after tetracycline withdrawal (0, 2, 4, 6, 8,
10, 12, 16, 24, 32 and 48hrs after tetracycline removal). MYC was used as a positive control. MAX mRNA level was not found to be affected by MYC
induction in P493 cells (not shown).
doi:10.1371/journal.pone.0002722.g002
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estrogenic compounds, the Myc-ER protein is bound by HSP90 in
the cytoplasm. Upon binding estrogenic compounds such as 4-
hydroxytamoxifen, the chimeric protein disengages from HSP90
and translocates to the nucleus, dimerizes with Max and activates
transcription even in the presence of cycloheximide, which blocks
protein synthesis. Hence, direct Myc target genes are considered to
be those that are responsive to Myc-ER in the presence of
cycloheximide. This system is confounded by changes in the
expression of specific genes induced by cycloheximide alone. In
this regard, we arbitrarily consider direct Myc targets in this
system to be induced at least 1.3 fold by Myc-ER in the presence
of cycloheximide but no more than 1.3 fold by cycloheximide
alone (Figure 5a).
Using the Myc null rat fibroblast (HO.15) expressing MYC-ER
[35], we found that cycloheximide alone perturbed the expression
of many nucleotide metabolic genes. Nonetheless, among 4
biologically independent experiments, 2 with regular culture
medium and 2 deprived of serum to eliminate cell proliferative
effects of Myc induction, PPAT and DHODH behaved as direct
Myc target genes (Figure 5b). All the other genes examined,
except GUK1, responded to the MYC-ER induction early in the
time course (2–4 hrs after the estrogenic compound treatment).
The expression of most of the genes were affected by cyclohex-
Figure 3. The expression of selected key nucleotide synthesis genes is responsive to MYC in hepatocytes in vivo. LAP-tTA X TRE-Myc
transgenic mouse conditionally expresses MYC proto-oncogene in hepatocytes. Male littermates withdrawn from doxycycline at birth overexpressed
MYC. Littermates withdrawn from doxycycline remained tumor-free up to day 3 (d3) but all developed liver tumors by day 11 (d11). Newborn mice
continuously treated with doxycycline remained free of disease. In both groups (with or without doxycycline treatment), 3 mice were sacrificed at
each time point (d3, d6, and d11) and the RNA extract from each liver sample was subjected to real-time PCR analysis for the expression of key genes.
Bar graphs represent mRNA expression of human MYC and each nucleotide biosynthetic enzyme gene in the pathway relative to 18S rRNA control.
doi:10.1371/journal.pone.0002722.g003
Figure 4. MYC binds to the regulatory regions of de novo nucleotide synthetic genes in B cells. Chromatin immunoprecipitation assay
demonstrates direct Myc binding to the nucleotide synthesis genes in P493-6 cells. Chromatin from P493-6 cells with or without tetracycline
treatment for 48 hours were precipitated with either anti-Myc or control IgG as indicated. The promoter or intronic sequence of each gene was
quantitatively amplified by real-time PCR. Bar graphs represent Myc binding to chromatin regions that contain promoters (ATIC, CTPS, DHODH, GART,
GMPS, IMPDH2, and PFAS), exons (RRM1) or introns (ADSL, ADSS, IMPDH1, NME1, PPAT/PAICS, and UMPS). Note that PPAT and PAICS are shown
together because they share a bidirectional promoter. Significant binding is .0.02% total input.
doi:10.1371/journal.pone.0002722.g004
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S1 and S2) [35]. Hence, the noise imparted by cycloheximide
alone profoundly limits the use of this system to identify direct
target genes in the nucleotide biosynthesis pathway.
Myc regulates the de novo purine and pyrimidine
synthetic genes in multiple biological systems
Table 2 summarizes the results from experiments we
performed to delineate the direct regulation of the nucleotide
biosynthetic genes by Myc. We examined the response of
nucleotide biosynthetic gene expression to Myc in vitro in the B
cell model and rat fibroblasts, and in vivo in the transgenic mouse
model. ChIP of Myc binding to nucleotide biosynthetic genes
performed in B cells and gene expression determined in B cells,
MYC-ER rat fibroblasts or mouse livers indicate that the vast
majority of nucleotide biosynthetic genes are probably direct Myc
targets. PPAT, catalyzing the first step of purine synthesis, and
DHODH, an enzyme generating uridine in the middle of the
pyrimidine synthesis pathway, were validated as direct c-MYC
target genes by all criteria. The other genes listed could still be
directly regulated by MYC but failed to survive the criterion set by
the MYC-ER system, which is confounded by noise imparted by
cycloheximide itself.
Figure 5. PPAT and DHODH are direct c-MYC target genes in the HO.15 MYC-ER system. (A) The experiment design was shown in the
diagram. We set the following criteria to identify direct MYC target genes: 1) A.1.3 fold induction of expression by 4-OHT with or without
cycloheximide; 2) A,1.3 fold induction of expression by cycloheximide alone. (B) PPAT and DHODH fulfilled the criteria in the majority of the
experiments. Bar graphs represent mRNA expression of either PPAT or DHODH relative to 18S rRNA control as determined by real-time PCR in HO.15
MYC-ER cells with regular medium (+FCS; light bars represent the expression at 0, 2, 4,10 hr) or with serum starvation (-FCS; black bars represent the
expression at 0, 2, 4,10 hr). One representative experiment is shown for each group from 4 biologically independent experiments.
doi:10.1371/journal.pone.0002722.g005
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enzyme in purine de novo synthesis, increased with MYC induction
both in vitro and in vivo. Furthermore the promoter regions of
both genes are bound directly by Myc, suggesting that they are
direct Myc targets which did not respond accordingly in the MYC-
ER system (supplemental Figure S3). The putative direct
regulation of IMPDH2 by Myc is further underscored by the
highly statistically significant co-expression of MYC and IMPDH2
(Pearson correlation coefficient .0.85) in microarray experiments
among 73 human tissues or cells and 6 human cell lines (http//
symatlas.gnf.org/SymAtlas).
Loss of IMPDH activity inhibits cell proliferation and
survival of P493 B cells
Because many nucleotide metabolic genes appear to be directly
regulated by Myc, we sought to determine the effects of loss of
function of a specific enzyme, IMPDH, in purine metabolism on
Myc-mediated cell proliferation and growth. In particular, we wish
to delineate whether inhibition of IMPDH in high MYC
expressing cells would simply deprive cells of guanosine and cause
a G1-S checkpoint arrest or cause S-phase stress with apoptosis as
an exit strategy for the perturbed cells. To determine if IMPDH is
essential for MYC stimulation of cell proliferation, we used
mycophenolic acid (MPA), the active metabolite of the well-known
clinical immunosuppressant Cellcept and specific inhibitor of
IMPDH1 and IMPDH2 [46]. MPA inhibited P493-6 cell
population growth in a dose-dependent manner with dose ranges
that are clinically achievable (Figure 6A). We also found that
guanosine, which is converted first to guanine and then to GMP
through HGPRT, could partly rescue the proliferative inhibitory
effect of MPA (Figure 6B) [46]. We also studied the Ramos
human Burkitt lymphoma cell line, and found that it is similarly
inhibited by MPA (Figure 6C) and also rescued by low doses of
guanosine (Figure 6D). Intriguingly, high doses of guanosine
inhibit cell proliferation that is associated with apoptosis and cell
cycle arrest (data not shown). Hence, guanosine’s own growth
inhibitory effects at high concentrations confound its ability to
rescue MPA inhibition. As such, we presumably could not use a
sufficiently high concentration of guanosine to replenish the
deficient state caused by MPA.
We next determined whether MPA diminishes P493-6 cell
growth through apoptosis. Annexin V staining indicates that MPA
triggered moderate apoptosis that could be largely rescued by
guanosine (Figure 7). Similarly, we observed that the MPA-
treated apoptotic Ramos cells were also rescued by guanosine
(Figure 7). Since MPA-induced apoptosis was almost fully
rescued by guanosine, apoptosis is unlikely to account fully for
the slowed population doubling with exposure to MPA. Hence, we
determined the effects of MPA on the cell cycle. P493-6 cells
synchronized by double thymidine block were released in the
presence or absence of MPA and cells were harvested at 4, 8, and
12 hours for flow cytometry (Figure 8A). Staining of cells for
DNA content reveals that MPA treated cells persisted longer in S
phase at 4 and 8 hours as compared with control cells or cells
treated with MPA but rescued with guanosine. These studies
suggest that MPA causes a delay in S phase.
To ascertain the effects of MPA on S phase, P493-6 cells were
doubly labeled with BrdU and 7-amino-actinomycin D (7-AAD)
for flow cytometry, which provides a measure of DNA synthesis
via BrdU incorporation and distribution of cells in the different
phases of the cell cycle via DNA content determined by 7-AAD
staining. Studies were performed after treatment with MPA with
and without guanosine rescue (Figure 8B). MPA treated P493-6
cells display a population of S-phase cells that have severely
blunted incorporation of BrdU that could be rescued by
guanosine, but not by adenosine or inosine (Figure 8B). We
note in the guanosine-rescued cells, however, a change in the
morphology of the BrdU and 7-AAD 2-dimensional flow
Table 1. Response of nucleotide biosynthetic enzyme genes
to MYC in HO15.MYC-ER cells
Gene Symbol
Induction time
point Fold change
Direct/
Inconclusive
ADSL 2hr 1.9–2.5 I
AK2 2hr 1.8–2.6 I
CAD 2hr 3.4–6.8 I
CTPS 2hr 2.7–4.4 I
DHODH 2hr 1.9–5.2 D
GART 2hr 2.3–8.1 I
GMPS 2hr 2.4–6.6 I
GUK1 no NC I
IMPDH1 2hr 1.9–5.9 I
IMPDH2 2hr–4hr 1.4–2.7 I
PAICS 2hr 1.3–4.0 I
PFAS 2hr 2.3–3.8 I
PPAT 2hr 3.5–11.4 D
Note: Induction time point was determined by the time point when the
induction .1.3 fold in the majority of the 4 independent experiments. Direct/
Inconclusive was determined by the arbitrary criteria: 4-OHT6CHX.1.3,
CHX,1.3, D: direct, I: inconclusive
doi:10.1371/journal.pone.0002722.t001
Table 2. Responses of genes encoding nucleotide biosynthesis enzymes to MYC
ADSL ADSS AK2 ATIC CAD CTPS DHODH GART GMPS IMPDH1 IMPDH2 NME PAICS PFAS PPAT RRM UMPS
A V V V VV VVV V V VV V V V
BV V V X V
C V V V VV VXV V V VV V V V
D X X X XV XXX X XX V
A: MYC responsiveness in human B cell in vitro,
B: MYC responsiveness in mouse hepatocyte in vivo,
C: MYC direct binding in human B cell in vitro,
D: HO.15 MYC-ER system, from 4 independent biological experiments
V=positive, X=negative or inconclusive, Empty=not checked
doi:10.1371/journal.pone.0002722.t002
Myc and Nucleotide Metabolism
PLoS ONE | www.plosone.org 8 July 2008 | Volume 3 | Issue 7 | e2722cytometric dot plot. In particular, the S-phase BrdU arc, which
normally curves down toward the G2M fraction of cells, is
increased and peaked over the G2M region of the rescued cells.
We surmise that while additional dGTP provided by guanosine is
sufficient to allow additional incorporation of BrdU, the MPA-
treated cells reaching G2M are not able to divide in the time
window of the BrdU pulse. The blunted BrdU incorporation with
MPA treatment suggests that DNA stress due to limited dGTP
results in slowed DNA replication and diminished cell prolifera-
tion. We similarly found that the blunting of BrdU incorporation
by MPA in Ramos cells could be fully rescued by guanosine
(Figure 8C). Furthermore, we observed that MPA treatment
activated the phosphorylation of H2AX (cH2AX) that could be
rescued by guanosine in both P493-6 (Figure 8D) and Ramos
cells (Figure 8E). These observations are compatible with DNA
stress induced by MPA depletion of dGTP, particularly at 500nM
MPA which caused an S phase arrest or delay. In aggregate, the
studies suggest that an ongoing maintenance of nucleotide pools is
necessary for normal DNA replication, which could be stressed by
imbalance in these pools particularly in Myc-driven cells. These
findings also strongly suggest that the upregulation of IMPDH1
and IMPDH2 by MYC is essential for the proper transit of cells
through S phase, such that interruption of IMPDH function results
in an S phase delay or arrest that is accompanied by evidence of
replication stress and apoptosis.
Discussion
MYC is not only a proto-typical oncogene when activated in
cancers, but it is also a master regulator of normal cell growth, cell
proliferation and metabolism. In this regard, Myc as a transcrip-
tional regulator has been shown to regulate a number of cellular
metabolic functions including its upregulation of glycolytic genes
and genes involved in oxidative phosphorylation and mitochon-
drial biogenesis. The coupling of energy metabolism and the cell
cycle machinery by Myc ensures that adequate energy is attained
for DNA synthesis. Hence, we sought to determine in this study
whether Myc also couples cell cycle progression with regulation of
nucleotide metabolism.
A balanced pool of dNTPs is not only required for the fidelity of
DNA replication, but a total increase in the pool during S phase is
also essential for cell proliferation [47,48]. Previous studies have
shown that regulation of this pool is critical, such that an increase
in any component of the pool would lead to misincorporation of
nucleotides, resulting in mutagenesis [48]. Although the balance of
the dNTP pool is regulated largely by the numerous enzymes
catalyzing the inter-conversion of dNTPs, how the cell increases
the total dNTP pool in synchrony with the cell cycle and DNA
replication machinery is largely unknown [47]. Here, we
demonstrate that one of the key regulators of cell cycle, MYC,
can also directly activate genes involved in purine and pyrimidine
biosynthesis and prepare the cells ready for cell cycle transition.
To identify direct Myc target genes, it is crucial to determine if
the target genes are directly bound by Myc and their expression
responds to Myc induction. ChIP is the only easily accessible
method that provides direct evidence for the in situ association of
a transcription factor to a specific target gene. We observed that
the majority of the genes in the nucleotide biosynthetic pathways
are directly bound by Myc. Furthermore the expression of these
genes also peaked after the induction of Myc, thereby supporting
the direct regulation of purine and pyrimidine biosynthetic genes
by Myc.
Figure 6. Mycophenolic acid (MPA) inhibits proliferation in P493-6 cells (left panels) and Ramos human Burkitt’s lymphoma cell line
(right panels). Cell proliferation was analyzed by using colorimetric microplate assay in which tetrazolium salt was bioreduced to orange product. Y-
axis represents the absorbance measurement at 450 nm. Error bars represent standard deviations derived from three independent measurements. (A)
Growth rates of P493-6 cells at different concentrations of MPA. (B) Growth rates of MPA-treated P493-6 cells with guanosine supplement. (C) Growth
rates of Ramos cells at different concentration of MPA. (D) Growth rates of MPA-treated Ramos cells with guanosine supplement.
doi:10.1371/journal.pone.0002722.g006
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genes is the induction of a target gene in the MYC-ER system in
the presence of cycloheximide. As discussed above, the inhibition
of protein synthesis by cycloheximide is expected to prevent
synthesis of a secondary factor that could activate secondary
responsive genes. Hence, genes that respond to MYC-ER in the
presence of cycloheximide are considered to be direct Myc targets.
Although hypothetically appealing as a principle, the MYC-ER
system is confounded by the effects of cycloheximide itself on the
mRNA levels of specific genes. In this regard, the MYC-ER system
is a highly stringent system for the inclusion of direct Myc targets,
but its limitation prevents its use to eliminate genes as direct targets
of Myc. In particular, it is possible that a feed-forward loop could
be driving a direct Myc target such that Myc induces a
hypothetical transcription factor X, which together with Myc are
both required to activate a direct Myc target gene. The use of
cycloheximide would prevent the induction of factor X and hence
blocks the induction of a feed-forward loop direct Myc target. In
our experience, the use of cycloheximide is associated with
significant noise in the mRNA levels of specific genes in the
nucleotide metabolic pathways. Well-known direct Myc targets
such as the CAD (carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase) did not behave as a direct
Myc target in our current study[29]. Hence, the lack of the typical
pattern of MYC-ER responsiveness with or without cycloheximide
should not be used to exclude genes as direct c-MYC targets.
Notwithstanding these caveats, PPAT and DHODH survived the
MYC-ER criterion and were found to be bona fide direct Myc
targets that are involved in purine and pyrimidine biosynthesis.
Intriguingly, MYC was found to directly activate the expression
of SHMT1, and SHMT2, which are enzymes involved in single
carbon metabolism and are essential for dNTP synthesis [32].
SHMT1 and SHMT2 donate single carbons to tetrahydrofolate
for the methylation of dUMP to dTMP by thymidylate synthase,
which was demonstrated to be a direct MYC target [49]. SHMT2
was previously discovered as a gene that could partially rescue the
diminished growth of rat fibroblasts lacking both copies of c-MYC
[32]. Our work indicates that MYC globally activates nucleotide
biosynthesis by directly transactivating virtually all genes involved
in purine and pyrimidine synthesis. In this fashion, the upregula-
tion of cell cycle genes, such as cyclin D2 and CDK4, by MYC is
coupled with an increase in dNTP nucleotide pool through direct
activation of nucleotide biosynthetic genes. Nucleotide metabolic
genes are hence not just ‘housekeeping’ genes.
The coupling of cell cycle traversal with nucleotide biosynthesis
is likely to involve the E2F family members since ribonucleotide
Figure 7. Mycophenolic acid (MPA) induces apoptosis in P493-6 and Ramos cells. Cells with designated treatments were subjected to
annexin V staining with 7-AAD and flow cytometry after 48 hours. Cells in the lower right quadrant, which are annexin-positive but 7-AAD-negative,
represent the apoptotic population. Necrotic or late apoptotic cells are 7-AAD-positive. The number indicates the percentage of the cells in each
quadrant.
doi:10.1371/journal.pone.0002722.g007
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bioinformatics analysis of Myc binding sites identified by ChIP-
PET revealed that the consensus binding site for E2F is highly
statistically enriched in DNA fragments associated with Myc [33].
Analysis of target genes with both Myc and E2F consensus sites
reveal a group that are directly involved in DNA replication, such
as MCM3, MCM4 and CDC6. In addition, analysis of the
nucleotide metabolic gene promoters also reveals an enrichment of
E2F sites. It is notable that Myc can induce E2F1 as a direct target,
and in this regard Myc and E2F1 could participate in a putative
feed-forward loop with nucleotide metabolic genes as direct targets
of both transcription factors. We surmise that the orchestration
between the cyclin-CDK axis, the DNA replication machinery and
nucleotide pool regulation involve coordinating transcriptional
Figure 8. Mycophenolic acid (MPA) slows DNA replication in P493-6 cells. (A) P493-6 cells were synchronized with double thymidine block.
Cells were incubated with 2mM thymidine for 12 hours, washed and incubated with normal growth medium for another 12 hours, and underwent a
second thymidine treatment for 12 hours. After washing, cells were subsequently treated with either methanol vehicle or MPA and guanosine as
indicated. Cells were collected for cell cycle profile analysis at different time points (4 h, 8 h, and 12 h) after release from double thymidine block. Cell
cycle profiles were analyzed by flow cytometry using PI staining. Numbers indicate the percentage of the cells in each cell cycle phase (G1/S/G2M).
(B) DNA replication and cell cycle profile were examined by BrdU uptake assay. P493-6 cells were pulsed with BrdU for 30 minutes before fixation and
subsequent staining. Anti-BrdU FITC antibody was used for measuring the BrdU incorporation. DNA content was assessed with 7-AAD staining. MPA-
treated cells were incubated concurrently with the indicated nucleotide (A=25 mM adenosine; G=25 mM guanosine; I=25 mM inosine) supplement
for 48 hrs before subjected to the analysis. (C) BrdU uptake assay in Ramos cells treated with MPA or with both MPA and 25 mM guanosine(G). Cells
were processed as described in Panel 8B. (D) Immunoblot demonstrating the expression of c-H2AX, a marker for DNA double strand breaks, in MPA-
treated P493-6 cells. Protein lysates from cells with designated conditions were harvested 48 hrs after guanosine treatment. In the groups receiving
both MPA and guanosine supplement, the treatment started concurrently. (E) c2H2AX expression in MPA-treated Ramos cells with or without 25 mM
guanosine.
doi:10.1371/journal.pone.0002722.g008
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members in this context is beyond the scope of the current work.
Nucleotide biosynthesis has been a cornerstone target for cancer
chemotherapy that has contributed to the remarkable responses of
many cancers including lymphoid malignancies. In fact, some of
the more profound immunosuppressants, such as MPA and
leflunomide, are inhibitors of nucleotide biosynthesis that is clearly
required for normal lymphocytic immune function. We sought to
determine the influence of MPA, which inhibits IMPDH function
and hence reduction of GMP, on the proliferation, apoptosis and
BrdU incorporation of the human P493-6 B cells bearing an
inducible MYC construct. Although not unexpected, MPA at
clinically relevant levels caused a significant growth inhibition.
This inhibition, however, could be partly rescued by guanosine.
While guanosine could fully rescue MPA-induced apoptosis, it is
unable to rescue the S-phase arrest, indicating a dominant effect of
MPA on S-phase arrest.
In summary, we demonstrate that MYC directly regulates genes
involved in purine and pyrimidine biosynthesis. The global
regulation of virtually all genes involved is consistent with the
concept of metabolic control analysis (MCA) which has demon-
strated that beyond the traditional concept of rate-limiting
biochemical steps, the activation of many points along a
biosynthetic pathway is essential for the increased flux of
metabolites toward the end product [52]. While increased
nucleotide flux is clearly required for normal DNA replication,
we surmise that deregulated MYC could create enhanced
expression of nucleotide metabolism genes, which would in turn
abnormally elevates the nucleotide pools that could contribute to
genomic instability. The effects of deregulated nucleotide metab-
olism pathways downstream of MYC will require additional
studies, for which our work has provided a firm foundation.
Supporting Information
Figure S1 Changes in pyrimidine biosynthetic enzymes gene
expression with induction of MYC in HO.15 Myc-ER cells. Time
course of gene expression determined by microarray analysis in
HO.15 Myc-ER cells with and without 4-OHT. Blue line: without
4-OHT; Red line: with 4-OHT. Solid line: average over replicates,
Dashed line=single replicates. Time points are 0, 1, 2, 3, 4, 5, 6,
8,10,12,16, 20 and 24 hours [35].
Found at: doi:10.1371/journal.pone.0002722.s001 (0.81 MB TIF)
Figure S2 Changes in purine biosynthetic enzymes gene
expression with induction of MYC in HO.15 Myc-ER cells. Time
course of gene expression in HO.15 Myc-ER cells with and
without 4-OHT as determine by microarray analysis. Blue line:
without 4-OHT; Red line: with 4-OHT. Solid line: average over
replicates, Dashed line:single replicates. Time points 0, 1, 2, 3, 4,
5, 6, 8,10,12,16, 20 and 24 hours [35].
Found at: doi:10.1371/journal.pone.0002722.s002 (1.41 MB TIF)
Figure S3 IMPDH1 and IMPDH2 are directly responsive to
MYC induction. (A) Myc binding to target genes in P493-6 cells
following MYC induction was measured. The inset shows an
immunoblot of Myc expression in P493-6 cells withdrawn from
tetracycline. ChIP was performed with P493-6 cells at different
time points (0 hr, 6 hr, 10hr, and 26 hr) after withdrawal of
tetracycline. Values indicate the percentage of total input DNA.
(B) Myc induces IMPDH1 or IMPDH2 expression that correlates
direct Myc binding to these genes. Bar graphs represent mRNA
expression of each nucleotide synthesis gene relative to 18S rRNA
control as determined by real-time PCR in P493-6 cells.
Found at: doi:10.1371/journal.pone.0002722.s003 (1.07 MB TIF)
Table S1 Response of nucleotide biosynthetic genes to MYC
Found at: doi:10.1371/journal.pone.0002722.s004 (0.06 MB
DOC)
Table S2 Primers used for real-time PCR assays
Found at: doi:10.1371/journal.pone.0002722.s005 (0.06 MB
DOC)
Table S3 Primers used for ChIP assays
Found at: doi:10.1371/journal.pone.0002722.s006 (0.04 MB
DOC)
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